Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051130 | 0.78 | USP2 (0.42) | MEN1KMT2ATHRBLMNAMMP9 | |
| SCHEMBL867377 | 0.76 | TSHR (0.46) | MEN1KMT2ATHRBLMNAMMP9 | |
| SCHEMBL13790899 | 0.76 | MEN1 (0.33) | MEN1KMT2ATHRBHSD17B10MMP9 | |
| SCHEMBL151135 | 0.74 | THRB (0.57) | MEN1KMT2ATHRBALDH1A1 | |
| SCHEMBL19757251 | 0.74 | LMNA (0.55) | THRBLMNAHSD17B10TDP1 | |
| SCHEMBL1123354 | 0.72 | EPHX2 (0.44) | MEN1KMT2ATHRBALDH1A1 | |
| SCHEMBL20613893 | 0.72 | LPAR5 (0.38) | MMP9MMP8MMP14ALDH1A1 | |
| SCHEMBL29518886 | 0.72 | TDP1 (0.49) | MEN1KMT2ATHRBHSD17B10TDP1 | |
| SCHEMBL10051133 | 0.72 | TGFBR1 (0.35) | MEN1KMT2A | |
| SCHEMBL12036308 | 0.72 | MEN1 (0.47) | MEN1KMT2ATHRBLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987410-B2 | Terminal unsaturated, glycidol-based macromonomers, polymers obtainable therefrom, preparation and use | BYK-CHEMIE GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120165414-A1 | TERMINAL UNSATURATED, GLYCIDOL-BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PREPARATION AND USE | BYK-CHEMIE GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165414-A1 | TERMINAL UNSATURATED, GLYCIDOL-BASED MACROMONOMERS, POLYMERS OBTAINABLE THEREFROM, PREPARATION AND USE | OXER1, OXGR1, ACSL3 | MEN1 3020/4885KMT2A 2609/4885THRB 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.